MacroGenics, Inc. (MGNX)Healthcare | Biotechnology | Rockville, United States | NasdaqGS
4.13 USD
+0.05
(1.225%)
⇧
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 4.10 -0.03 (-0.030%) ⇩ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 4:08 a.m. EDT
The investment case here is fractured by a brutal multi-year reality check. While the balance sheet remains technically solvent with a fortress-like current ratio, the business has been decimated by the market, dropping nearly 95% over the last nine years. The trailing twelve months show a collapse in profitability with negative operating margins and free cash flow, indicating the core engine is currently burning capital without generating returns. Although the stock recently rallied 26%, this appears to be a technical rebound off the lows rather than a fundamental turnaround, especially given the latest year-over-year decline. The lack of a dividend and the heavy put option positioning at lower strikes suggest the market views this as a speculative recovery play with a hard floor, not a stable income or growth vehicle. Until the company demonstrates sustained revenue growth and a return to positive cash flows, the risk of permanent capital impairment remains high. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.072843 |
| MSTL | 0.073023 |
| AutoARIMA | 0.076445 |
| AutoTheta | 0.100976 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 36% |
| H-stat | 2.30 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.208 |
| Excess Kurtosis | -1.29 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 81.851 |
| Revenue per Share | 2.763 |
| Market Cap | 263,081,776 |
| Forward P/E | -3.62 |
| Beta | 1.22 |
| Profit Margins | -8.33% |
| Website | https://www.macrogenics.com |
As of Aug. 22, 2026, 4:08 a.m. EDT: Speculators are positioning asymmetricly for downside protection rather than upside speculation. Put open interest is heavily concentrated at the $3.00 strike, creating a significant barrier for further declines, while call activity is sparse and mostly focused near the money or slightly out-of-the-money. This structure suggests a 'floor' mentality where traders are betting on a bounce off the lows rather than a breakout to the analyst targets.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.3448277 |
| Address1 | 9,704 Medical Center Drive |
| All Time High | 41.0 |
| All Time Low | 0.99 |
| Ask | 5.15 |
| Ask Size | 2 |
| Average Analyst Rating | 2.3 - Buy |
| Average Daily Volume10 Day | 436,410 |
| Average Daily Volume3 Month | 862,419 |
| Average Volume | 862,419 |
| Average Volume10Days | 436,410 |
| Beta | 1.217 |
| Bid | 2.96 |
| Bid Size | 2 |
| Book Value | 0.674 |
| City | Rockville |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.13 |
| Current Ratio | 2.956 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 4.15 |
| Day Low | 3.98 |
| Debt To Equity | 81.851 |
| Display Name | MacroGenics |
| Earnings Call Timestamp End | 1,742,502,600 |
| Earnings Call Timestamp Start | 1,742,502,600 |
| Earnings Timestamp End | 1,794,513,600 |
| Earnings Timestamp Start | 1,794,513,600 |
| Ebitda | -32,169,000 |
| Ebitda Margins | -0.18367 |
| Enterprise To Ebitda | -3.882 |
| Enterprise To Revenue | 0.713 |
| Enterprise Value | 124,868,776 |
| Eps Current Year | -0.74 |
| Eps Forward | -1.14 |
| Eps Trailing Twelve Months | -1.59 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 301 251 5321 |
| Fifty Day Average | 4.2334 |
| Fifty Day Average Change | -0.10339975 |
| Fifty Day Average Change Percent | -0.024424754 |
| Fifty Two Week Change Percent | 134.48276 |
| Fifty Two Week High | 5.08 |
| Fifty Two Week High Change | -0.9499998 |
| Fifty Two Week High Change Percent | -0.18700784 |
| Fifty Two Week Low | 1.29 |
| Fifty Two Week Low Change | 2.8400002 |
| Fifty Two Week Low Change Percent | 2.2015505 |
| Fifty Two Week Range | 1.29 - 5.08 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,381,411,800,000 |
| Float Shares | 57,010,393 |
| Forward Eps | -1.14 |
| Forward P E | -3.6228073 |
| Free Cashflow | -69,411,128 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 293 |
| Fullday Change | 0.0500002 |
| Fullday Change Percent | 1.22549 |
| Fullday Price | 4.1 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | -0.00745 |
| Gross Profits | -1,304,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03481 |
| Held Percent Institutions | 0.77528 |
| Implied Shares Outstanding | 63,700,187 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland. |
| Long Name | MacroGenics, Inc. |
| Market | us_market |
| Market Cap | 263,081,776 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_600911 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -101,056,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 260,533,764 |
| Number Of Analyst Opinions | 4 |
| Open | 4.06 |
| Operating Cashflow | -63,724,000 |
| Operating Margins | -0.42191002 |
| Payout Ratio | 0.0 |
| Phone | 301 251 5172 |
| Post Market Change | -0.03000021 |
| Post Market Change Percent | -0.72639734 |
| Post Market Price | 4.1 |
| Post Market Time | 1,787,959,805 |
| Previous Close | 4.08 |
| Price Eps Current Year | -5.5810814 |
| Price Hint | 4 |
| Price To Book | 6.1275964 |
| Price To Sales Trailing12 Months | 1.5021056 |
| Profit Margins | -0.08332 |
| Quick Ratio | 2.918 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.28571 |
| Region | US |
| Regular Market Change | 0.0500002 |
| Regular Market Change Percent | 1.22549 |
| Regular Market Day High | 4.15 |
| Regular Market Day Low | 3.98 |
| Regular Market Day Range | 3.98 - 4.15 |
| Regular Market Open | 4.06 |
| Regular Market Previous Close | 4.08 |
| Regular Market Price | 4.13 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 540,919 |
| Return On Assets | -0.080520004 |
| Return On Equity | -2.25846 |
| Revenue Growth | 3.78 |
| Revenue Per Share | 2.763 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 63,700,187 |
| Shares Percent Shares Out | 0.113900006 |
| Shares Short | 7,256,491 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 5,690,928 |
| Short Name | MacroGenics, Inc. |
| Short Percent Of Float | 0.1181 |
| Short Ratio | 9.93 |
| Source Interval | 15 |
| State | MD |
| Symbol | MGNX |
| Target High Price | 11.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 7.25 |
| Target Median Price | 7.0 |
| Total Cash | 173,304,992 |
| Total Cash Per Share | 2.721 |
| Total Debt | 35,092,000 |
| Total Revenue | 175,142,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.59 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.942 |
| Two Hundred Day Average Change | 1.1880002 |
| Two Hundred Day Average Change Percent | 0.403807 |
| Type Disp | Equity |
| Volume | 540,919 |
| Website | https://www.macrogenics.com |
| Zip | 20,850 |